Nashville-based ophthalmology pharmaceutical company Harrow Health and its affiliate Melt Pharmaceuticals each made announcements this week. 

Melt develops rapidly dissolving tablets free of opioids for use as an alternative to IVs for sedation and anesthesia during surgeries. In a Wednesday press release, the company announced that it paid back $13.5 million lent by Harrow in September 2021 to conduct trials on MELT-300. 

C.J. Stinson

C.J. Stinson